Jenna Payesko

The chief executive officer of C2N Diagnosis spoke about an investigational blood test used for screening of amyloid pathology in individuals being assessed for Alzheimer disease diagnosis.

If the C2N brain amyloidosis test becomes FDA approved, this could be the first blood-based screening test to predict brain amyloid PET scan results in those with memory complaints or dementia.

Approximately 60% of the patients with ALS are already excluded from clinical trial participation at the day of diagnosis, but investigators think that 60% is an underestimate.

CAP-1002 is the only therapy to show reduction in myocardium scar and an improvement of localized cardiac function in late-stage Duchenne accompanied cardiomyopathy.

The mist-like nasal spray acts rapidly and is well tolerated and is formulated using Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville discussed when to best perform routine EEG in patients with epilepsy.

The director of the Center for Neurodegeneration and Translational Neuroscience and director emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health, shared thoughts on his hope for the future of Alzheimer disease, among other topics.

Overall, there were no statistically significant or clinically relevant effects of bedtime administration of lemborexant on next-morning driving performance in healthy adult and elderly volunteers.

The director of the Center for Neurodegeneration and Translational Neuroscience and director emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health, spoke about the emerging therapies and biomarkers in Alzheimer disease.

The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.

The pediatric epileptologist at Nicklaus Children’s Hospital discussed the long-term seizure freedom data that looked at the effectiveness of perampanel which demonstrated a gratifying response in seizure control for patients with secondarily generalized seizures.

The NDA was based on the results of 2 pivotal phase 3 clinical studies, SUNRISE 1 and SUNRISE 2, which enrolled approximately 2000 patients, as well as safety studies.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about when clinicians should initiate and stop anti-seizure medications.

A new research project is underway to improve the pre-surgical evaluation of pediatrics with medical refractory epilepsy.

The director of the sleep clinic and assistant professor of neurology at Harvard Medical School discussed what has been learned about pediatric narcolepsy in the last decade, as well as what questions remain unanswered.

The director of the Jefferson Comprehensive Epilepsy Center and the Jefferson Clinical Neurophysiology Laboratory provided insight about the phase 3 safety trial of cenobamate.

Because the drug candidate has shown a competitive efficacy and safety profile compared with existing drugs in recent partial focal epilepsy studies, a phase 3 study was initiated.

The approval adds medication-refractory tremor from Parkinson disease to the current indication for incisionless, focused ultrasound thalamotomy.

The principal research scientist at Neuroscience Research Australia and an associate professor of medicine at the University of New South Wales provided more insight into the latest knowledge regarding sleep apnea phenotyping and its role in the development of targeted pharmacotherapies.

The results of the study found that those taking IRL790 had a mean reduction of 8.2% in dyskinesia scores compared to placebo.

Patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days for both monthly and quarterly dosing regimens.

If approved, diroximel fumarate may offer a differentiated gastrointestinal tolerability profile for patients with relapsing forms of multiple sclerosis.

The study found 33 additional single nucleotide polymorphisms with stronger relationships with a single subgroup.

The trial results indicate that EBV-specific adoptive T cell therapy is well tolerated and further back this approach in efficacy trials.

The Senior Medical Director at Eli Lilly discussed the clinical impact galcanezumab could have for patients with cluster headache if approved by the FDA.

The Senior Medical Director of Eli Lilly and Company spoke to lasmiditan and the clinical impact the investigational therapy could have for patients with acute migraine.

In quick cognitive tests routinely used in primary care, misclassification by at least 1 assessment occured in 36.7% participants, whereas only 1.7% were misclassified by all 3.

Recent data has shown that a start low, go slow approach with cenobamate may mitigate the risk of drug reaction with eosinophilia and systemic symptoms syndrome.

The Professor of Medicine at the University of New South Wales highlighted the latest knowledge in sleep apnea phenotyping and its crucial role in the development of targeted pharmacotherapies to treat OSA.

If approved, BHV-0223 would become the only formulation of riluzole that doesn't require swallowing tablets or liquids, offering an important delivery alternative for the standard-of-care treatment of ALS.